Show simple item record

dc.contributor.authorRubio Duarte, Andrés Felipespa
dc.contributor.authorLindarte, H. H.spa
dc.contributor.authorParra, G. A.spa
dc.date.accessioned2021-02-08T18:29:06Z
dc.date.available2021-02-08T18:29:06Z
dc.date.issued2020-03
dc.identifier.issn2389-9786spa
dc.identifier.urihttp://hdl.handle.net/20.500.12749/12156
dc.description.abstractLos inhibidores del PCSK-9 se presentan como una excelente alternativa de tratamiento en aquellos casos de hipercolesterolemia que no alcanzan las metas con tratamiento usual con estatinas de alta potencia y ezetimiba, adicionalmente en los pacientes con intolerancia a estatinas que necesiten tener metas de colesterol LDL. En este caso exponemos la posibilidad de titular el tiempo de aplicación de PCSK-9i de acuerdo con las metas de los niveles de LDL.spa
dc.format.mimetypeapplication/pdfspa
dc.language.isospaspa
dc.relationhttp://revistaendocrino.org/index.php/rcedm/article/view/568/746
dc.relation.urihttp://revistaendocrino.org/index.php/rcedm/article/view/568
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/*
dc.sourceRevista Colombiana de Endocrinología, Diabetes & Metabolismo; Volumen 07, Número 01 (Marzo 2020); páginas 43-44spa
dc.sourceRevista Colombiana de Endocrinología, Diabetes & Metabolismospa
dc.titleRespuesta supraóptima a los inhibidores de PCSK-9: ¿es obligatorio darlos cada 2 semanas? a propósito de un casospa
dc.title.translatedOver optimum response to PCSK-9 inhibitors: ¿is it mandatory to supply them every 2 weeks?, about a casespa
dc.publisher.grantorUniversidad Autónoma de Bucaramanga UNABspa
dc.rights.localAbierto (Texto Completo)spa
dc.publisher.facultyFacultad Ciencias de la Saludspa
dc.publisher.programPregrado Medicinaspa
dc.type.driverinfo:eu-repo/semantics/article
dc.type.localArtículospa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1
dc.subject.keywordsHypercholesterolemiaeng
dc.subject.keywordsHydroxymethylglutaryl-CoA Reductase Inhibitorseng
dc.subject.keywordsEvolocumabeng
dc.subject.keywordsMedicineeng
dc.identifier.instnameinstname:Universidad Autónoma de Bucaramanga - UNABspa
dc.identifier.reponamereponame:Repositorio Institucional UNABspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersion
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
dc.relation.referencesAlenghat FJ, Davis AM. Management of blood cholesterol. JAMA. 2019;321(8):800-1.spa
dc.relation.referencesCicero AF, Bove M, Borghi C. Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia. Expert Opin Drug Metab Toxicol. 2018;14(1):9-15.spa
dc.relation.referencesAmerican Diabetes Association. Cardiovascular disease and risk ma-nagement: standards of medical care in diabetes. Diabetes Care. 2019;2(1):S103-23.spa
dc.relation.referencesAlenghat FJ, Davis AM. Management of blood cholesterol. JAMA. 2019;321(8):800-1spa
dc.relation.referencesCicero AF, Bove M, Borghi C. Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia. Expert Opin Drug Metab Toxicol. 2018;14(1):9-15spa
dc.relation.referencesAmerican Diabetes Association. Cardiovascular disease and risk ma-nagement: standards of medical care in diabetes. Diabetes Care. 2019;2(1):S103-23spa
dc.contributor.cvlachttps://scienti.minciencias.gov.co/cvlac/visualizador/generarCurriculoCv.do?cod_rh=0001774484*
dc.contributor.googlescholarhttps://scholar.google.com/citations?user=_WII30IAAAAJ&hl=es*
dc.contributor.orcidhttps://orcid.org/0000-0001-9091-5367*
dc.subject.lembMedicinaspa
dc.subject.lembCiencia de la saludspa
dc.identifier.repourlrepourl:https://repository.unab.edu.cospa
dc.description.abstractenglishThe PCSK-9 inhibitors are presented as an excellent alterna-tive treatment in those cases of hypercholesterolemia that do not reach goals with high intensity statin treatment and ezetimibe, additionally in patients with statin intolerance who need to have LDL cholesterol goals. In this case we expose the possibility to treat to target LDL goals and use PCSK-9i later than 2 weeks.eng
dc.subject.proposalHipercolesterolemiaspa
dc.subject.proposalInhibidores de hi-droximetilglutaril-CoA reductasasspa
dc.subject.proposalEvolocumabspa
dc.type.redcolhttp://purl.org/redcol/resource_type/ART
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadas 2.5 Colombia*


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 2.5 Colombia
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 2.5 Colombia